- Open Access
- Open Peer Review
No evidence of differential effects of SFA, MUFA or PUFA on post-ingestive satiety and energy intake: a randomised trial of fatty acid saturation
Nutrition Journalvolume 9, Article number: 24 (2010)
High fat diets have long been associated with weight gain and obesity, and the weak satiety response elicited in response to dietary lipids is likely to play a role. Suppression of appetite and food intake has consistently been shown to be diminished with high fat relative to either high protein or carbohydrate meals. There is however some evidence that the satiating capacity of lipids may be modulated when physicochemical properties are altered, but studies investigating the effect of lipid saturation on appetite have generated inconsistent findings. This study investigated the effects of changes in fatty acid saturation on post-ingestive satiety and energy intake.
High-fat (HF) test breakfasts (2.0 MJ) containing 26 g lipid were given to 18 healthy, lean men in a 3 treatment randomised cross-over design, each treatment separated by a washout of at least 3 days. The breakfasts were high in saturated (SFA, 65% of total fat), polyunsaturated (PUFA, 76%) or monounsaturated (MUFA, 76%) fatty acids, and comprised 2 savoury muffins. Participants rated appetite sensations using visual analogue scales (VAS) to assess palatability immediately following the meals, and hunger and fullness prior to the HF breakfast and throughout the day. Energy intake was measured by covert weighing of a lunch meal which was served 3.5 h after the breakfast, and from which the participants ate ad libitum.
There was no difference in VAS ratings of pleasantness, visual appearance, smell, taste, aftertaste and overall palatability between the 3 high-fat test breakfasts. However, there was also no differential effect of the 3 treatments on ratings of hunger, fullness, satisfaction or prospective food consumption during the 3.5 h following the breakfast meal and over the full 6 h experiment. Energy and macronutrient intake at lunch also did not differ between treatments (mean, sem; SFA: 5275.9 ± 286.5 kJ; PUFA: 5227.7 ± 403.9 kJ; MUFA: 5215.6 ± 329.5 kJ; P > 0.05). The maximum difference in energy intake between treatments was less than 2%.
There was no evidence of a difference in post-ingestion satiety between high fat meals which differed in saturation profile in this group of lean, healthy men.
A high intake of dietary fat has long been implicated in the development of obesity with a positive association between a high-fat (HF), high-energy dense diet and a high body mass index (BMI) [1, 2]. Whether there is a causal relationship between dietary fat and the current high levels of obesity continues to be debated however, [3–8] as does dietary fat as a primary driver of hyperphagia, or overconsumption, during weight gain. In a number of early studies dietary fat was shown to exert a weaker satiating effect than isoenergetic amounts of either carbohydrate (CHO) or protein in most [9–11], although not all [12, 13] studies. Possibly factors such as palatability , high energy density [10, 11, 15–17] and relatively weak oxidative feedback of dietary lipids [15, 18–20] may play a role in overconsumption of lipid-rich foods , the latter hypothesis having been recently revisited . The inability of lipids to mount a strong postprandial satiety-related hormone response relative to the other macronutrients may also contribute [17, 22, 23].
There is also some evidence to suggest that the association of a HF diet with weight gain and obesity may in part depend on the saturation of the fatty acids (FA) consumed and that unsaturated, and in particular polyunsaturated FAs (PUFA), may be associated with lower adiposity [24–26]. Several studies have shown that the rate of postprandial fat oxidation, purported to act as a satiety feedback signal, is negatively related to the degree of saturation [27–33]. In early studies degree of saturation was also linked with changes in putative appetite modifiers such as CCK , insulin and serotonin . In addition, effects on ad libitum energy intake (EI) have been reported. Whilst there is some evidence of PUFA having the strongest and MUFA the weakest suppression of food intake, clinical studies are inconsistent and variable. A gastrointestinal infusion study showed high-PUFA Intralipid® (a fat emulsion comprising largely soybean oil) and linoleic acid (18:2) to decrease intake when compared with a no-fat saline control, whilst carbon chain length (CCL) -matched stearic acid (C18:0, SFA) and oleic acid (C18:1, MUFA) did not . In a feeding study of CCL-matched fats, both high-PUFA and high-SFA meals decreased food intake when compared with high-MUFA meals , and a second infusion study showed lauric acid (C12:0 SFA) but not the longer chain oleic acid (C18:1 MUFA) to decrease food intake relative to a saline control . Conversely, other studies have found less convincing [39, 40] or no evidence of saturation affecting ad libitum EI or appetite ratings [41–43], or with response differing by gender .
This lack of consensus led to our current study which investigated whether changes in the saturation profile of a high-fat breakfast meal affected postprandial appetite sensations and food consumption at the subsequent meal using a study design which we have previously shown to be sensitive to manipulations in energy and fat content . Based on prior studies we hypothesized that there may be a satiety hierarchy of PUFA > SFA > MUFA when a high fat meal balanced for both energy and total fat content is consumed.
Participants and Methods
Lean male participants (BMI 18-25 kg/m2), aged between 18-55 years were recruited into this intervention trial through poster, newspaper and electronic advertisement. Body weight and height were measured whilst fasted on 2 consecutive occasions and mean BMI recorded. Participants were from the local community including tertiary institutions. Exclusion criteria were self-reported current or previous history of overweight or obesity, current or recent history (previous 6 months) of dieting including commercial weight loss programs or weight loss surgery, eating disorders or significant restraint , smoking, hypertension, cardiovascular disease, diabetes mellitus (type I or II), and any significant metabolic, endocrine or gastrointestinal disease. Normal lipid profile, full blood count and fasting blood glucose levels were also ensured at screen. None of the participants were taking medications known to affect appetite or weight regulation. Written consent was obtained from each of the participants. Ethical approval for this study was obtained from the Northern Regional Ethics Committee, Auckland, New Zealand.
This was a randomised, 3 treatment cross-over trial where the effects of a HF test breakfast supplemented with SFA, PUFA or MUFA were assessed through subjective visual analogue scales (VAS) and ad libitum EI at a single lunch meal. The primary objective of measurement of food intake at the lunch meal was not revealed to the participants prior to the study. All participants attended the Human Nutrition Unit (HNU) on three separate occasions between which they returned home for a washout period of at least 3 days where they were asked to resume their habitual diet and exercise pattern. Participants were asked to abstain from alcohol and strenuous physical activity for 24 hours prior to the study-day, and to complete a 24-hour dietary recall and physical activity questionnaires. Physical activity was estimated using a questionnaire evaluating activities according to duration and intensity using the PEPSA (Physical Exercise Programme for Sedentary Adults) points system  to assess whether differences in activity on the day prior to the test may have confounded measured outcomes of appetite.
Participants were asked to fast from 2000 h the previous evening, including liquids, not to exercise in the morning and to arrive at the Unit using motorized transport. At the clinic body weight and waist circumference were measured fasted, and adverse events and/or medications used between treatments recorded. Immediately upon arrival at 7 am the participants were given 200 ml water which they were required to drink in full, after which they were asked to complete baseline VAS rating their subjective feelings of hunger, fullness, satisfaction and prospective food consumption . A venous cannula was also inserted for sequential collection of blood samples throughout the morning, and lipid profile, glucose and insulin concentrations were measured. The HF test breakfast was served at 0830 h and participants were asked to consume the test-meal in full but at their own pace within a 15 minute period. The exact duration of the meal was recorded. No further foods were allowed throughout the morning until an ad lib lunch meal was served 210 minutes later, at 1200 h, to assess energy and macronutrient intake. Lunch was served individually in a quiet dining room with minimal distractions. VAS ratings were measured throughout the morning and for 2 hours after completion of the ad lib lunch. All measurements of food intake were covert. Participants remained at the HNU during each study-day and were allowed to read, write or undertake other such sedentary activities but were not allowed to sleep.
High-fat test breakfasts
The 3 breakfast treatments were HF (50 en% fat) and isoenergetic (2.0 MJ), comprising 2 savoury muffins (ingredients: flour, skimmed milk powder, eggs, tomato, ham, test lipid). The lipids were included as an integral part of the recipe and baked into the muffins. The test breakfast was served at 0830 h, co-presented with 300 ml water. The treatments differed in FA composition and were (i) high-SFA (from butter fat), (ii) high-PUFA (from safflower oil) or (iii) high-MUFA (from olive oil). The energy and macronutrient composition of the 3 test breakfasts was calculated using the dietary program FoodWorks™ (Professional Edition, Version 2.10.136, 1998-2000; Xyris Software) and are shown in Table 1.
Visual Analogue Scales
Participants rated their hunger, fullness, satisfaction and prospective consumption (how much do you think you could eat now?) using VAS . Subjective feelings were recorded by placing a vertical line across 100 mm scales, anchored at either end by statements; "I am not hungry at all/I am not full at all/I am completely empty/Nothing at all" on the left and "I am as hungry I have ever been/I am totally full/I cannot eat another bite/A large amount" on the right. VAS rating how thirsty, energetic and relaxed the participants felt were included as a distraction from the main outcome. VAS were completed prior to the test meal and 15, 30, 45, 60, 90, 120, 150, 180, 210, [ad lib lunch], 270, 330 and 390 minutes after the participant began consumption of the test breakfast. Immediately after breakfast, participants also rated the pleasantness, visual appeal, smell, taste, aftertaste and overall palatability of the breakfast using separate 100-mm VAS [9, 47]. These questions were anchored on the left by each of the statements "not at all pleasant/bad visual appeal/bad smell/bad taste/strong aftertaste/bad palatability" and on the right by the statements "as pleasant as I have ever tasted/good visual appeal/good smell/good taste/no aftertaste/good palatability".
The ad libitum lunch consisted of a restricted buffet-style meal with predominantly cold and one hot meal choice, along with a selection of beverages. In an attempt to avoid over-consumption the variation of meal items offered was limited. Participants were advised that they could eat as much or as little as they chose and that they were to remain in the room for a period of 45 minutes. The items presented at the ad lib buffet meal, along with their serving weight, energy and macronutrient content are shown in Table 2. All discrete items (eg bread) were presented as small portions (e.g. quarter slices of bread), and all items were served in excess. Covert weighing of each meal item was carried out before and after lunch to allow calculation of energy and macronutrient intake. Food items were weighed to the nearest 0.5 g (Sartorius AG, Goettingen, Germany), and energy and macronutrient content of foods consumed calculated using the dietary program FoodWorks (Professional Edition Version 2.10.136 1998-2000; Xyris Software).
VAS data were analysed using a repeated measures Linear Mixed Model ANOVA (SAS: PROC MIXED, SAS version 8.0, SAS Institute Inc, Cary, NC, 2001). The participant, the dietary treatment, the intervention period, and the study day were included in the procedure, as was the treatment/time interaction which addressed whether the trajectory over time during the intervention period differed between treatments (diet*time). MANOVA was also used to generate a full model for VAS incorporating all dependent variables. Energy and macronutrient intake data from the ad lib lunch meal was analysed using univariate ANOVA (SAS: PROC MIXED, SAS version 8.0, SAS Institute Inc, Cary, NC, 2001). Univariate ANOVA was also used to determine any differences in EI or physical activity level on the day prior to each treatment visit (Day-1). The trial was analysed on the basis of intention to treat (ITT), hence all data from all treatment visits completed were included in the analysis. Missing data was assumed missing at random and no data imputation was performed. Statistical significance was based on 95% limits (P < 0.05). Participant characteristics are presented as mean, standard deviation (mean, SD). Efficacy endpoints are presented as mean, standard error of the mean (mean, SEM).
Eighteen (18) male participants were randomized into the study, of which 17 completed all 3 treatments. One participant completed only 2 treatments (SFA, MUFA; PUFA treatment was not completed) due to relocation overseas, hence a total of 53 of the scheduled 54 study visits were completed. Participant characteristics are shown in Table 3. They were on average young, lean men. All participants were normoglycaemic with no evidence of hyperlipidaemia or hypertension. On the day prior to intervention there was no significant difference in reported EI (mean, SEM) between treatments (SFA: 8338, 738 kJ/day; PUFA: 8259, 640 kJ/day; MUFA: 7919, 790 kJ/day; treatment, P > 0.05) or reported level of physical activity (treatment, P > 0.05). Physical activity level (mean, SEM) was assessed through hours spent on mild-moderate activity (SFA: 2.1, 0.4 h; PUFA: 2.4, 0.4 h; MUFA: 2.8, 0.6 h), minutes spent on vigorous-strenuous activity (SFA: 4.2, 2.9 m; PUFA: 8.8, 5.6 m; MUFA:10.8, 5.7 m), hours standing (SFA: 4.1, 0.7 h; PUFA: 3.4, 0.5 h; MUFA: 4.0, 0.6 h), hours sitting and watching TV/video (SFA: 4.5, 0.9 h; PUFA: 5.1, 0.8 h; MUFA: 4.2, 0.9 h), and total PEPSA points (SFA:16.9, 4.3; PUFA: 21.2, 6.5; MUFA: 28.1, 10.2). Between participants results were highly variable and there were no significant treatment effects (treatment, P > 0.05).
Visual Analogue Scales
There was no difference in VAS ratings of pleasantness, visual appearance, smell, taste, aftertaste and overall palatability between the 3 HF test breakfasts when assessed immediately following consumption (treatment, P > 0.05, Figure 1), indicating that participants were unable to differentiate between the saturation profiles using visual and sensory cues in this blinded trial. VAS were also used to assess subjective feelings of hunger and satiety throughout the experiment. Figure 2 shows the mean ratings for hunger, fullness, satisfaction and prospective food consumption during the 6 hours following the test breakfast for each of the high-SFA, high-PUFA and high-MUFA treatments. As expected following a 2MJ meal, hunger and prospective consumption significantly decreased and fullness and satisfaction significantly increased immediately following each of the treatments, and then gradually returned to baseline by 210 mins (time, P < 0.01). Consumption of the ad lib lunch also induced significant changes in VAS-rated measures of appetite and satiety during the afternoon. There was however no significant difference in mean ratings of hunger, fullness, satisfaction or prospective consumption between the 3 treatments when measured over the 3.5 hours between the test breakfast and ad lib lunch meal (0-210 mins; all, treatment*time P > 0.05) or when measured throughout the full study day (0-390 mins; all, treatment*time P > 0.05). The use of MANOVA to combine VAS measurements for all treatments was also unable to identify a significant difference between treatments either before lunch or over the full study day (treatment*time, P > 0.05). Analysis of the sequential blood collects also showed there to be no difference between circulating levels of serum cholesterol, triacylglycerol (TAG), glucose or insulin between the SFA, MUFA and PUFA treatments (all, treatment*time P > 0.05).
Energy and macronutrient intake at the ad libitumlunch
Mean total EI and energy contributed by CHO, fat and protein respectively at the ad lib lunch is presented for each treatment in Figure 3. There was no significant difference in total EI between lipid treatments (treatment, P > 0.05). Mean (SEM) EI at lunch was 5275.9 (286.5) kJ, 5227.7 (403.9) kJ, and 5215.6 (329.5) kJ following the SFA-, PUFA-, and MUFA-rich breakfasts respectively. The maximum difference between treatments was less than 2%. When macronutrient intake was compared between treatments there was no significant difference in CHO, fat or protein nor weight of food consumed at the lunch meal (treatment, P > 0.05).
There was no evidence from this study that changes made to the fatty acid saturation of a high fat breakfast altered subjective hunger ratings or energy intake at the subsequent lunch meal in a group of healthy male participants. This is consistent with a number [41–43] but not all [36–38, 40] previously published studies, and there are several issues concerning study design which it is important to consider.
There are a wide range of published methods by which short-term appetite regulation has been assessed but consensus is yet to be achieved as to best practice . The methodology in our current trial was based primarily on the lipid emulsion trials of Burns and colleagues [49–51] where small manipulations in lipids at a test breakfast induced significant changes in EI at a subsequent lunch meal. Arguably, the long separation between the intervention and the ad lib lunch (>3 hours) in these trials may make changes in eating behaviour more difficult to effect than studies where an outcome meal is given only 60 or 90 minutes following the test treatment. In our current trial however the ad lib energy intake was consistent with the recorded postprandial feelings of hunger and fullness which also did not differ across lipid treatments. It is possible that the varied item buffet-style lunch may have encouraged overconsumption, decreased sensitivity and masked differential effects, but again it is notable that a multi-item buffet lunch has previously been shown to be sensitive to effects of acute lipid manipulations [49–51]. We have previously shown it to be sensitive to changes in energy content at a breakfast meal . Pleasantness, visual appeal, smell, taste, after-taste and palatability were all well matched between treatments in our current trial, and differences in the energy density of the test lipids were small.
There is little consensus as to whether degree of lipid saturation may play a role in regulation of body weight and adiposity through mechanisms driving changes in either intake or oxidation. Whilst epidemiological evidence of an association between lipid saturation and adiposity in studies such as the Quebec Family Study  suggest that saturation may influence either intake or oxidation, evidence remains scant. Friedman originally proposed the hypothesis that oxidation of macronutrients following a meal may exert a negative feedback on appetite and eating behavior, and hence control the satiating power of a given nutrient . Whilst human studies have been unable confirm this mechanism , there are some data which do show an oxidative gradient may exist and may be driven in part by FA saturation [25, 27–33] and hence the hypothesis remains of interest . Interestingly, FA saturation has also been shown to impact postprandial hormone response including the peptides insulin  and CCK [34, 36] which may drive changes in intake, although again the data remains inconclusive [53–55].
Much of the evidence for effect of saturation on EI has been derived from acute studies of intake of similar design to our current trial and also from acute GI infusion trials, several of which show increased satiety effects of PUFA. Intestinal infusion of Intralipid (54% PUFA linoleic acid, 29% MUFA oleic acid) and PUFA (linoleic acid), but not SFA (stearic acid) or MUFA (oleic acid) emulsions tended to decrease EI relative to a saline control in a study of men given a restricted lunch meal . The effects were modest however with no significant differential effects between the 4 fat loaded treatments. This was supported in part by Lawton et al (2000) in a CCL-matched feeding study which demonstrated decreased ratings of appetite and a trend, albeit non-significant, towards lower ad lib EI over the rest of the day following a high-PUFA (linoleic acid) and SFA (stearic-oleic blend) lunch meal compared with a lunch rich in MUFA (oleic acid) . A second study by the same authors was unable to confirm these results, although merging data from the 2 studies did support the greater satiety effects of PUFA . A more recent intraduodenal infusion study of the C12:0 SFA lauric acid versus longer chain C18:1 MUFA oleic acid showed a decrease in EI following the SFA but not MUFA treatment relative to a saline control . Conversely, there are also studies which find MUFA to be more satiating than PUFA [39, 40]. For example, Burton-Freeman et al (2005) found that mean VAS scores of appetite satisfaction were greater following a high-oleic safflower oil (high-MUFA) compared with a walnut oil (high-PUFA) preload, although it is notable that this result was not substantiated by 4 other appetite-related VAS or subsequent ad lib EI at lunch . Finally there are further trials which are consistent with our current study and which have been unable to detect a difference in ratings of appetite or EI between meals of varying saturation profile [41–43]. It is apparent that a clear effect of lipid saturation on satiety has yet to be established.
Some variability in outcome may in part be due to differences in methods. Important aspects of trials assessing postprandial changes in appetite may include number and characteristics of participants; lipid dose, composition and route of administration; inter-meal interval; and composition and variety of foods offered at the ad lib outcome meal. These have been summarized in Table 4. Of the trials so far conducted, all were small sample studies (8-25 participants) conducted predominantly in lean, healthy participants. Dose of lipid administered does not appear to unduly bias outcome since studies by Lawton  and Flint  both administered high doses of lipid (>50 g fat), yet only the Lawton study conducted in lean participants showed differential effects of FA saturation. The fact that delivery of lower doses, such as our current trial (26 g), are sufficient to elicit a response was demonstrated by Kamphuis and colleagues where a 25 g lipid supplement differentially altered EI . Burton-Freeman  administered a low dose (9-13 g) lipid treatment yet observed significant effects on some VAS-assessed satiety ratings, albeit these did not result in suppression of EI at a subsequent test meal. The route of lipid administration is likely to also be important and it is notable that 2 [38, 56] of the 4 [37, 40] trials where a differential response was elicited delivered the lipid treatments via GI infusion hence bypassing early sensory and cognitive signaling. Whilst it is difficult to find methodological issues directly responsible for the variable outcome of the studies to date, each of the trials appears robust in its approach, it is clear that a strong case cannot be built for enhanced satiety with high-SFA, MUFA or PUFA based on current evidence.
In this study we were unable to show differential changes in postprandial feelings of hunger or fullness, or changes in energy intake at a lunch meal when alterations were made to the fatty acid saturation of a high-fat breakfast. Lipid dose, the interval between test-breakfast and ad libitum outcome lunch, and the composition of the ad lib meal have all been identified as areas which may bias outcome. In this study we administered a 26 g lipid test meal which was well matched for sensory outcomes between treatments, 3.5 hours prior to a free choice lunch meal. Whether a higher dose lipid product administered as a preload rather than test meal, i.e. closer to the lunch meal, would elicit an appetite response is unknown. Certainly there is little consensus on effects of dietary lipid composition on appetite control from previous studies. Whether appetite may be altered by longer term and sustained changes in dietary fatty acid composition also remains to be demonstrated.
analysis of variance
body mass index
carbon chain length
human nutrition unit
multivariate analysis of variance
monounsaturated fatty acid
Physical Exercise Programme for Sedentary Adults
polyunsaturated fatty acid
standard error of the mean
saturated fatty acid
visual analogue score.
Lissner L, Heitmann BL: Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr. 1995, 49 (2): 79-90.
Bray GA, Paeratakul S, Popkin BM: Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav. 2004, 83 (4): 549-555. 10.1016/j.physbeh.2004.08.039.
Willett WC: Dietary fat and obesity: an unconvincing relation. Am J Clin Nutr. 1998, 68 (6): 1149-1150.
Hill JO, Astrup A: What diets should we be recommending for obesity?. Obesity Reviews. 2003, 4 (2): 77-78. 10.1046/j.1467-789X.2003.00103.x.
Astrup A: Carbohydrates as macronutrients in relation to protein and fat for body weight control. Int J Obes. 2006, 30 (S3): S4-S9. 10.1038/sj.ijo.0803485.
Astrup A, Grunwald GK, Melanson EL, Saris WH, Hill JO: The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes. 2000, 24 (12): 1545-1552. 10.1038/sj.ijo.0801453.
Pirozzo S, Summerbell C, Cameron C, Glasziou P: Should we recommend low-fat diets for obesity?. Obesity Reviews. 2003, 4 (2): 83-90. 10.1046/j.1467-789X.2003.00099.x.
Field AE, Willett WC, Lissner L, Colditz GA: Dietary fat and weight gain among women in the Nurses' Health Study. Obesity (Silver Spring). 2007, 15 (4): 967-976. 10.1038/oby.2007.616.
Rolls BJ, Kim-Harris S, Fischman MW, Foltin RW, Moran TH, Stoner SA: Satiety after preloads with different amounts of fat and carbohydrate: implications for obesity. Am J Clin Nutr. 1994, 60 (4): 476-487.
Blundell JE, Burley VJ, Cotton JR, Lawton CL: Dietary fat and the control of energy intake: evaluating the effects of fat on meal size and postmeal satiety. Am J Clin Nutr. 1993, 57 (5 Suppl): 772S-777S. discussion 777S-778S
Lawton CL, Burley VJ, Wales JK, Blundell JE: Dietary fat and appetite control in obese subjects: weak effects on satiation and satiety. Int J Obes. 1993, 17 (7): 409-416.
Poppitt SD, McCormack D, Buffenstein R: Short-term effects of macronutrient preloads on appetite and energy intake in lean women. Physiol Behav. 1998, 64 (3): 279-285. 10.1016/S0031-9384(98)00061-4.
French S, Robinson T: Fats and food intake. Curr Opin Clin Nutr Metab Care. 2003, 6: 629-634. 10.1097/00075197-200311000-00004.
Stubbs RJ, Whybrow S: Energy density, diet composition and palatability: influences on overall food energy intake in humans. Physiol Behav. 2004, 81: 755-764. 10.1016/j.physbeh.2004.04.027.
Poppitt SD, Prentice AM: Energy density and its role in the control of food intake: evidence from metabolic and community studies. Appetite. 1996, 26 (2): 153-174. 10.1006/appe.1996.0013.
Rolls BJ, Roe LS, Meengs JS: Reductions in portion size and energy density of foods are additive and lead to sustained decreases in energy intake. Am J Clin Nutr. 2006, 83: 11-17.
Raben A, Agerholm-Larsen L, Flint A, Holst JJ, Astrup A: Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake. Am J Clin Nutr. 2003, 77: 91-100.
Friedman MI: Fuel partitioning and food intake. Am J Clin Nutr. 1998, 67 (3): 513S-518.
Friedman MI, Tordoff MG, Ramirez I: Integrated metabolic control of food intake. Brain Res Bull. 1986, 17 (6): 855-859. 10.1016/0361-9230(86)90099-7.
Arvaniti K, Richard D, Tremblay A: Reproducibility of energy and macronutrient intake and related substrate oxidation rates in a buffet-type meal. Br J Nutr. 2000, 83 (5): 489-495.
Langhans W: Fatty acid oxidation in the energostatic control of eating - A new idea. Appetite. 2008, 51: 446-451. 10.1016/j.appet.2008.06.014.
Monteleone P, Bencivenga R, Longobardi N, Serritella C, Maj M: Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab. 2003, 88: 5510-5514. 10.1210/jc.2003-030797.
Pedersen-Bjergaard U, Høst U, Kelbaek H, Schifter S, Rehfeld JF, Faber J, Christensen NJ: Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest. 1996, 56: 497-503. 10.3109/00365519609088805.
Doucet E, Almeras N, White MD, Despres JP, Bouchard C, Tremblay A: Dietary fat composition and human adiposity. Eur J Clin Nutr. 1998, 52 (1): 2-6. 10.1038/sj.ejcn.1600500.
Piers LS, Walker KZ, Stoney RM, Soares MJ, O'Dea K: Substitution of saturated with monounsaturated fat in a 4-week diet affects body weight and composition of overweight and obese men. Br J Nutr. 2003, 90 (3): 717-727. 10.1079/BJN2003948.
Storlien LH, Hulbert AJ, Else PL: Polyunsaturated fatty acids, membrane function and metabolic diseases such as diabetes and obesity. Curr Opin Clin Nutr Metab Care. 1998, 1 (6): 559-563. 10.1097/00075197-199811000-00014.
Jones PJ, Schoeller DA: Polyunsaturated:saturated ratio of diet fat influences energy substrate utilization in the human. Metabolism. 1988, 37 (2): 145-151. 10.1016/S0026-0495(98)90009-9.
Jones PJ, Ridgen JE, Phang PT, Birmingham CL: Influence of dietary fat polyunsaturated to saturated ratio on energy substrate utilization in obesity. Metabolism. 1992, 41 (4): 396-401. 10.1016/0026-0495(92)90074-K.
Piers LS, Walker KZ, Stoney RM, Soares MJ, O'Dea K: The influence of the type of dietary fat on postprandial fat oxidation rates: monounsaturated (olive oil) vs saturated fat (cream). Int J Obes. 2002, 26 (6): 814-821. 10.1038/sj.ijo.0801993.
Soares MJ, Cummings SJ, Mamo JC, Kenrick M, Piers LS: The acute effects of olive oil v. cream on postprandial thermogenesis and substrate oxidation in postmenopausal women. Br J Nutr. 2004, 91 (2): 245-252. 10.1079/BJN20031047.
DeLany JP, Windhauser MM, Champagne CM, Bray GA: Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr. 2000, 72 (4): 905-911.
Jones PJ, Pencharz PB, Clandinin MT: Whole body oxidation of dietary fatty acids: implications for energy utilization. Am J Clin Nutr. 1985, 42 (5): 769-777.
Kien CL, Bunn JY, Ugrasbul F: Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. Am J Clin Nutr. 2005, 82 (2): 320-326.
Beardshall K, Frost G, Morarji Y, Domin J, Bloom SR, Calam J: Saturation of fat and cholecystokinin release: implications for pancreatic carcinogenesis. Lancet. 1989, 2 (8670): 1008-1010. 10.1016/S0140-6736(89)91017-9.
Mullen BJ, Martin RJ: The effect of dietary fat on diet selection may involve central serotonin. Am J Physiol. 1992, 263 (3 Pt 2): R559-563.
French SJ, Conlon CA, Mutuma ST, Arnold M, Read NW, Meijer G, Francis J: The effects of intestinal infusion of long-chain fatty acids on food intake in humans. Gastroenterol. 2000, 119 (4): 943-948. 10.1053/gast.2000.18139.
Lawton CL, Delargy HJ, Brockman J, Smith FC, Blundell JE: The degree of saturation of fatty acids influences post-ingestive satiety. Br J Nutr. 2000, 83 (5): 473-482.
Feltrin KL, Little TJ, Meyer JH, Horowitz M, Rades T, Wishart J, Feinle-Bisset C: Comparative effects of intraduodenal infusions of lauric and oleic acids on antropyloroduodenal motility, plasma cholecystokinin and peptide YY, appetite, and energy intake in healthy men. Am J Clin Nutr. 2008, 87: 1181-1187.
Burton-Freeman B: Sex and cognitive dietary restraint influence cholecystokinin release and satiety in response to preloads varying in fatty acid composition and content. J Nutr. 2005, 135 (6): 1407-1414.
Kamphuis MM, Westerterp-Plantenga MS, Saris WH: Fat-specific satiety in humans for fat high in linoleic acid vs fat high in oleic acid. Eur J Clin Nutr. 2001, 55 (6): 499-508. 10.1038/sj.ejcn.1601222.
MacIntosh CG, Holt SH, Brand-Miller JC: The degree of fat saturation does not alter glycemic, insulinemic or satiety responses to a starchy staple in healthy men. J Nutr. 2003, 133 (8): 2577-2580.
Flint A, Helt B, Raben A, Toubro S, Astrup A: Effects of different dietary fat types on postprandial appetite and energy expenditure. Obes Res. 2003, 11 (12): 1449-1455. 10.1038/oby.2003.194.
Alfenas RC, Mattes RD: Effect of fat sources on satiety. Obesity Res. 2003, 11 (2): 183-187. 10.1038/oby.2003.29.
Lithander FE, Strik CM, McGill AT, MacGibbon AK, McArdle BH, Poppitt SD: No effect of an oleoylethanolamide-related phospholipid on satiety and energy intake: a randomised controlled trial of phosphatidylethanolamine. Lipids Health Dis. 2008.
Stunkard AJ, Messick S: The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985, 29 (1): 71-83. 10.1016/0022-3999(85)90010-8.
Grant B, Wilson N: PEPSA Diary. 1993, Dunedin: PEPSA Ltd
Flint A, Raben A, Blundell JE, Astrup A: Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes. 2000, 24 (1): 38-48. 10.1038/sj.ijo.0801083.
Blundell JE, deGraaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, VanderKnaap H, et al: Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010,
Burns AA, Livingstone MB, Welch RW, Dunne A, Robson P, Lindmark L, Reid CA, Mullaney U, Rowland IR: Short-term effects of yoghurt containing a novel fat emulsion on energy and macronutrient intakes in non-obese subjects. Int J Obes. 2000, 24: 1419-1425. 10.1038/sj.ijo.0801430.
Burns AA, Livingstone MB, Welch RW, Dunne A, Reid CA, Rowland IR: The effects of yoghurt containing a novel fat emulsion on energy and macronutrient intakes in non-overweight, overweight and obese subjects. J Obes Relat Metab Disord. 2001, 25: 1487-1496. 10.1038/sj.ijo.0801720.
Burns AA, Livingstone MB, Welch RW, Dunne A, Rowland IR: Dose-response effects of a novel fat emulsion (Olibra) on energy and macronutrient intakes up to 36 h post-consumption. Eur J Clin Nutr. 2002, 56: 368-377. 10.1038/sj.ejcn.1601326.
Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J, Hermansen K: Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr. 1999, 69 (6): 1135-1143.
Poppitt SD, Keogh GF, Mulvey TB, Phillips A, McArdle BH, MacGibbon AK, Cooper GJ: Effect of moderate changes in dietary fatty acid profile on postprandial lipaemia, haemostatic and related CVD risk factors in healthy men. Eur J Clin Nutr. 2004, 58: 819-827. 10.1038/sj.ejcn.1601882.
Blundell JE: Serotonin and the biology of feeding. Am J Clin Nutr. 1992, 55 (1): 155S-159.
Flint A, Gregersen NT, Gluud LL, Møller BK, Raben A, Tetens I, Verdich C, Astrup A: Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies. Br J Nutr. 2007, 98: 17-25. 10.1017/S000711450768297X.
French S: Effects of dietary fat and carbohydrate on appetite vary depending upon site and structure. Br J Nutr. 2004, 92 (Suppl 1): S23-26. 10.1079/BJN20041137.
LactoPharma New Zealand provided the funding for this trial. We thank Glyn Muir, Shelley Baty and Nisha Patel who provided technical assistance during the study. We also thank the participants in this intervention trial.
Declaration of Competing interests
SDP, ATM, FEL, CMS, AKM received salary support and funding for this trial from LactoPharma, New Zealand. Other authors declare that they have no competing interests.
CM Strik was responsible for patient recruitment, screening and daily management of the trial as well as data entry and contribution to manuscript preparation; FE Lithander participated in patient recruitment, screening and oversaw trial management; AT McGill was the study physician and contributed to protocol design and regulatory procedures; AKH MacGibbon contributed to the design of the trial and provision of dietary treatments; BH McArdle was responsible for all statistical analyses; SD Poppitt was the senior author, and responsible for protocol design, data interpretation, trial supervision and regulatory procedures. All authors read and approved the final manuscript.